Related Experiment Video
Updated: May 29, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Chemotherapy for diffuse low-grade gliomas in adults
1INSERM U1028, CNRS UMR5292, service de neuro-oncologie, hôpital neurologique, hospices civils de Lyon, Lyon Neuroscience Research Center, neuro-oncology and neuro-inflammation team, 59 boulevard Pinel, Lyon, France. francois.ducray@chu-lyon.fr
Revue Neurologique
|September 13, 2011
Summary
Chemotherapy offers a promising treatment for adult diffuse low-grade gliomas (LGGs), a type of slow-growing brain tumor. This review examines current and future chemotherapy strategies, including response assessment and biomarkers for treatment effectiveness.
Area of Science:
- Neuro-oncology
- Clinical Neurology
- Cancer Research
Background:
- Diffuse low-grade gliomas (LGGs) are adult brain tumors with slow growth and potential for malignant transformation.
- Current standard treatments involve surgery and radiotherapy, but optimal timing for radiotherapy is debated.
- Chemotherapy is an emerging treatment option for LGGs, with ongoing research into its efficacy.
Purpose of the Study:
- To review advancements in chemotherapy for adult diffuse low-grade gliomas.
- To discuss methods for assessing treatment response to chemotherapy.
- To explore potential biomarkers predicting chemosensitivity in LGGs.
Main Methods:
- Literature review of past, recent, and ongoing studies on LGG chemotherapy.
- Analysis of response assessment techniques in clinical trials.
- Examination of research on predictive biomarkers for chemotherapy response.
Main Results:
- Chemotherapy is a viable and evolving treatment option for diffuse low-grade gliomas.
- Standardized response assessment criteria are crucial for evaluating chemotherapy efficacy.
- Biomarkers show potential for personalizing chemotherapy treatment decisions.
Conclusions:
- Chemotherapy plays an increasingly important role in managing adult diffuse low-grade gliomas.
- Further research is needed to optimize chemotherapy regimens and identify predictive biomarkers.
- Personalized treatment strategies incorporating chemotherapy hold promise for improved patient outcomes.
